News
Orforglipron: What to Know About Eli Lilly’s New Weight Loss Pill for Obesity
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...
5h
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...
Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White ...
The grandmother of Lilly Sullivan and Jack Sullivan, two children who have been missing from Nova Scotia since May 2, called ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 ...
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback